David Evans Wins NED Award

At the 4th Annual Non-Executive Director awards ceremony held at the Plaisterers Hall in London last month, serial entrepreneur David Evans was declared the Non Executive Director of the Year in the AIM quoted company category from a strong field of contenders. David was presented with his award for his work on the Board of Immunodiagnostics Systems Holdings. Other nominees in the group were esteemed NED’s, David Bailey and Alan Walker.

This award recognises David’s involvement in bringing to market some of the most successful diagnostic orientated life sciences companies over the past 10 years.

David was initially the Finance Director at Shield Diagnostic, a significant and rapidly growing company based in Dundee. He took over as CEO of Shield and led the merger with the Scandinavian diagnostic company,
Axis, to create the UK’s largest diagnostic company.

Since then, David has led the strategic development of a number of companies including BBI Holdings, Immunodiagnostics Systems and AIM’s most successful listing, year on year since its flotation, Epistem.

Commenting on the award David said: “I am delighted that the judging panel has seen fit to honour me with this award. The list of candidates contained many of the most well known entrepreneurs working in many
industries, so that makes this award even more important to me. Whenever I choose to get involved with a company, it is on the basis that I will be able to provide significant hands on expertise in an area I know well.

That has been rewarded through generating significant share holder value in each of those companies. In reality creating share holder value is a team effort and I am fortunate to be surrounded by some of the best individuals in the business, and recognise that the actions of one individual when combined with the skill sets of others is the fastest way to ensure business success. I’m delighted therefore to receive this award on behalf of all of those involved, recognition of all the hard work that goes on both at company level and through my own team of experts. The award recognises what has been achieved in the past, but I’m looking towards the future. With this in mind I’m delighted to announce the launch of Diagnostic Capital, which aims to raise £50m to exclusively invest in personalised medicine based diagnostic ventures. It will be the first of its type in the
UK, quoted on AIM and run by my own team. It will be the first time an opportunity such as this has existed to give institutions and private investors alike the chance to gain exposure to a number of exciting companies through one pooled vehicle.”